Is Cytomegalovirus Surveillance Necessary for Patients With Low Reactivation Risk in an Autologous Hematopoietic Cell Transplantation Setting?

Kaya A. H., Tekgunduz E., Akpinar S., Batgi H., Bekdemir F., Kayikci O., ...More

TRANSPLANTATION PROCEEDINGS, vol.49, no.8, pp.1911-1915, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 49 Issue: 8
  • Publication Date: 2017
  • Doi Number: 10.1016/j.transproceed.2017.05.007
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1911-1915
  • Eskisehir Osmangazi University Affiliated: Yes


Background. In an autologous hematopoietic cell transplantation (AHCT) setting, routine cytomegalovirus (CMV) surveillance is not indicated except in high-risk situations. On the other hand, some studies reported increased CMV reactivation in AHCT setting as a result of incorporation of novel agents into treatment algorithms, such as bortezomib and rituximab. We retrospectively analyzed CMV reactivation and infection rates in patients with no high-risk features, who were treated with AHCT.